Olin (OLN) Q4 2025 earnings summary

Executive summary

• Fourth quarter 2025 results were significantly below expectations, with a net loss of $85.7 million, due to operational issues, extended asset turnarounds, and raw material supply constraints, especially at the Freeport, Texas site.

• Value-first commercial approach preserved ECU values and supported long-term agreements, including a notable deal with Braskem to upgrade export EDC values.

• Epoxy segment achieved volume growth amid European capacity closures, while Winchester segment reduced commercial production to accelerate destocking.

• Aggressive inventory reductions and cost structure adjustments were implemented in the Winchester business in response to lower commercial ammunition demand.

• Structural cost reductions of $44 million were realized in 2025 through the Beyond250 initiative.

Financial highlights

• Generated $321 million in operating cash flow in Q4 2025, holding net debt flat versus year-end 2024.

• Achieved $248 million in cash from working capital reductions in 2025, excluding tax timing.

• Year-end 2025 available liquidity stood at $1 billion, with a cash balance of $167.6 million.

• Full-year 2025 adjusted EBITDA was $651.8 million, down from $873.9 million in 2024.

• Net loss for FY25 was $43.4 million, compared to net income of $105.0 million in FY24.

Outlook and guidance

• Q1 2026 earnings and adjusted EBITDA expected to be lower than Q4 2025 due to seasonally weaker demand and higher costs, especially in chlor-alkali and vinyls.

• Epoxy business expected to return to profitability in 2026, driven by cost reductions, new supply agreements, and European market growth.

• Winchester results projected to modestly improve with higher commercial ammunition volume and pricing, offsetting rising input costs.

• Full-year 2026 outlook for chlor-alkali remains challenging, with continued headwinds from global pricing and rising U.S. input costs.

• 2026 headwinds include higher raw material and turnaround expenses, lower 45V tax credit benefit, and increased stock-based compensation; tailwinds expected from caustic price benefits, Beyond250 cost savings, and improved EDC values from the Braskem agreement.